文献速递老年精神精神分裂症与精神病性障碍

极晚发精神分裂样精神病的氨磺必利随机对照试验(ATLAS)

Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
PubMed 文献 · Lancet Psychiatry · 2018-06-04

ATLAS 是一项随机、双盲、安慰剂对照试验,纳入 101 例极晚发(≥60 岁)精神分裂样精神病患者,比较每日 100 mg 氨磺必利与安慰剂。结果显示,氨磺必利在 12 周时改善 BPRS 评分优于安慰剂,继续治疗可维持获益,但严重不良事件在氨磺必利组更常见(差异未达统计学意义)。

要点

  • 低剂量氨磺必利(100 mg/日)在 12 周时改善精神病症状优于安慰剂。
  • 继续氨磺必利治疗可维持获益,换为安慰剂则症状恶化。
  • 氨磺必利组严重不良事件(感染、锥体外系反应)报告更频繁。

核心结论

  • 低剂量氨磺必利对极晚发精神分裂样精神病有效且耐受性良好,延长治疗可维持获益。

研究设计与样本

  • ATLAS 为随机、对照、双盲试验,从英国 25 个老年精神科服务机构招募 101 例极晚发精神分裂样精神病患者(BPRS≥30,无认知障碍)。
  • 参与者按 1:1:1 随机分入三组:A 组两阶段均用氨磺必利,B 组先用氨磺必利后换安慰剂,C 组先用安慰剂后换氨磺必利。
  • 治疗为口服氨磺必利 100 mg/日或安慰剂,第一阶段 12 周,第二阶段初始计划 24 周后改为 12 周。
  • 主要结局为 4、12、24 或 36 周时 BPRS 评估的精神病症状及因无效而中止试验治疗。
  • 分析采用改良意向性治疗,纳入至少接受一剂研究治疗的 92 例参与者。

主要发现

  • 研究期间 5 例死亡,均与治疗无关。

关键数值与推荐

  • 极晚发精神分裂样精神病定义为年龄≥60 岁起病,BPRS 评分≥30,无认知障碍。
  • 干预为口服氨磺必利 100 mg 每日一次,对照为安慰剂。
  • 主要结局指标为 BPRS 评分变化及因无效中止治疗。

临床怎么用

  • 对于极晚发精神分裂样精神病患者,可考虑使用低剂量氨磺必利(100 mg/日)改善精神病症状。
  • 治疗 12 周后若有效,继续维持治疗有助于保持获益;但需监测严重不良事件,尤其是感染和锥体外系反应。

局限性

  • 样本量较小(101 例随机,92 例纳入分析),可能影响统计效能。
  • 依从性欠佳,59 例(64%)完成第一阶段,34 例(58%)完成第二阶段治疗。
  • 严重不良事件在氨磺必利组更常见,但差异未达统计学显著性,需更大样本验证安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks. METHODS: The ATLAS double-blind controlled trial enrolled participants from 25 old age psychiatry services in the UK. Eligible participants (ie, those with a diagnosis of very late-onset schizophrenia-like psychosis and a Brief Psychiatric Rating Scale [BPRS] score of ≥30, without cognitive impairment) were randomly assigned (1:1:1) to one of three groups in a two-stage trial: amisulpride in stage 1 and 2 (group A), amisulpride then placebo (group B), or placebo then amisulpride (group C). Treatment (100 mg oral amisulpride daily vs placebo) was given for 12 weeks in stage 1 and, initially, 24 weeks then reduced to 12 weeks in stage 2. Participants, investigators, and outcome assessors were masked to treatment allocation. Primary outcomes were psychosis symptoms assessed by the BPRS at 4, 12, and 24, or 36 weeks, and trial treatment discontinuation for non-efficacy. The primary, secondary, and safety endpoints were all analysed in participants given at least one dose of study treatment in modified intention-to-treat analyses. This study is registered with EudraCT, number 2010-022184-35, and ISRCTN, number ISRCTN45593573. FINDINGS: Between Sept 27, 2012, and June 28, 2016, we recruited 101 participants. 92 (91%) of 101 participants took trial medication, of whom 59 (64%) completed stage 1 and 34 (58%) of these 59 participants completed stage 2 treatment. Despite suboptimal compliance, improvements in BPRS scores at 12 weeks were 7·7 points (95% CI 3·8-11·5, p=0·0002) greater with amisulpride (mean 11·9 points [SE 1·3]) than with placebo (4·2 points [1·0]). In stage 2, BPRS scores improved by a mean of 1·1 points (1·6) from 12 weeks to the final assessment in those who continued amisulpride but deteriorated by 5·2 points (2·0) in those who switched from amisulpride to placebo (difference 6·3 points [95% CI 0·9-11·7], p=0·024). Fewer participants who were allocated amisulpride than placebo stopped treatment because of non-efficacy in stage 1 (p=0·010) and stage 2 (p=0·031). Serious adverse events were reported more frequently in the amisulpride group than in the placebo group in stage 1 (p=0·057) and stage 2 (p=0·19). The most common serious adverse events were infection (five patients in the amisulpride group, three in the placebo group) and extrapyramidal side-effects (three patients in the amisulpride group, none in the placebo group). Five patients died during the study, one from a gastric ulcer bleed before treatment started (group B), two while taking stage 2 treatment (one in group A and one in group C), and two who stopped trial treatment in stage 1 and died many weeks later (one in group B and one in group C). No deaths were related to treatment. INTERPRETATION: Low-dose amisulpride is effective and well tolerated as a treatment for very late-onset schizophrenia-like psychosis, with benefits maintained by prolonging treatment. FUNDING: UK National Institute for Health Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Howard R, Cort E, Bradley R, et al. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry. 2018. PMID: 29880238. doi:10.1016/S2215-0366(18)30141-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。